BioQL Invest ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  16.4% 12.3% 12.2% 23.4% 17.4%  
Credit score (0-100)  11 18 19 3 9  
Credit rating  BB BB BB B B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Gross profit  -299 -12.5 -7.5 -7.8 -8.1  
EBITDA  -299 -12.5 -7.5 -7.8 -8.1  
EBIT  -299 -12.5 -7.5 -7.8 -8.1  
Pre-tax profit (PTP)  15,776.9 6,547.0 6,542.1 2,591.2 -8.1  
Net earnings  15,776.9 6,547.0 6,542.1 2,601.5 -4.4  
Pre-tax profit without non-rec. items  15,777 6,547 6,542 2,591 -8.1  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  7,017 6,610 6,652 153 78.9  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  7,026 6,617 6,659 161 86.4  

Net Debt  -446 -35.3 -109 -150 -72.3  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -299 -12.5 -7.5 -7.8 -8.1  
Gross profit growth  -3,296.2% 95.8% 40.0% -4.2% -4.0%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  7,026 6,617 6,659 161 86  
Balance sheet change%  4.1% -5.8% 0.6% -97.6% -46.3%  
Added value  -299.3 -12.5 -7.5 -7.8 -8.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  229.0% 96.0% 98.6% 76.0% -6.6%  
ROI %  229.3% 96.1% 98.7% 76.2% -7.0%  
ROE %  229.3% 96.1% 98.7% 76.5% -3.8%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  99.9% 99.9% 99.9% 95.3% 91.3%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  148.9% 282.3% 1,451.1% 1,924.8% 889.4%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  803.0 882.3 887.9 21.4 11.5  
Current Ratio  803.0 882.3 887.9 21.4 11.5  
Cash and cash equivalent  445.8 35.3 108.8 150.4 72.3  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  7,017.3 6,609.6 6,651.7 153.2 78.9  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0